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We previously observed that Pim-3 with serine/threonine kinase
activity, was aberrantly expressed in malignant lesions of endoderm-
derived organs, liver and pancreas. Because Pim-3 protein was
not detected in normal colon mucosal tissues, we evaluated Pim-3
expression in malignant lesions of human colon, another endoderm-
derived organ. Pim-3 was detected immunohistochemically in well-
differentiated (43/68 cases) and moderately differentiated (23/41
cases) but not poorly differentiated colon adenocarcinomas (0/5 cases).
Moreover, Pim-3 proteins were detected in adenoma (35/40
cases) and normal mucosa (26/111 cases), which are adjacent to
adenocarcinoma. Pim-3 was constitutively expressed in SW480
cells and the transfection with Pim-3 short hairpin RNA promoted
apoptosis. In the same cell line, a pro-apoptotic molecule, Bad, was
phosphorylated at Ser112 and Ser136 sites of phosphorylation that are
representative of its inactive form. Ser112 but not Ser136 phosphorylation
in this cell line was abrogated by Pim-3 knockdown. Furthermore, in
human colon cancer tissues, Pim-3 co-localized with Bad in all
cases (9/9) and with phospho-Ser112Bad in most cases (6/9).
These observations suggest that Pim-3 can inactivate Bad by
phosphorylating its Ser112 in human colon cancer cells and thus may
prevent apoptosis and promote progression of human colon cancer.
(Cancer Sci 2007; 98: 321–328)
Pim-3 was originally identified as the depolarization-inducedgene, KID-1, in PC12 cells, a rat pheochromocytoma cell
line.(1) Because KID-1 shows a high sequence similarity with the
proto-oncogene Pim family that expresses serine/threonine kinase
activity, it was renamed as Pim-3.(2) Accumulating evidence
indicates the potential involvement of other Pim family members,
Pim-1 and Pim-2, in various types of carcinogenesis.(3–6) Indeed,
Deneen and colleagues demonstrated that Pim-3 gene transcrip-
tion was enhanced in EWS/ETS-induced malignant transfor-
mation of NIH 3T3 cells.(7) Moreover, we revealed that Pim-3
was selectively expressed in malignant lesions but not
normal tissues of endoderm-derived organs, liver(8) and
pancreas.(9) These observations suggest the potential involvement
of Pim-3 in carcinogenesis, particularly in endoderm-derived
organs.
Apoptosis is an important mechanism during normal crypt
formation in another endoderm-derived organ, colon.(10) The
molecular mechanism of colon cancer progression is known to
involve several key events and mutation of a number of crucial
genes.(11) A partial suppression of apoptosis occurs as a result of
the inactivation of both alleles of the APC gene and the suppres-
sion of apoptosis allows APC-deficient cells to develop adeno-
matous polyps.(12) Further suppression of apoptosis occurs as
these cells develop additional genetic mutations and phenotypic
changes.(13) Thus, the dysregulation of apoptosis is crucially
involved in colon carcinogenesis.
Accumulating evidence indicates that Pim kinases can
phosphorylate substrates that regulate apoptosis, and that activated
Pim kinases might contribute to the pathogenesis of a wide variety
of malignancies.(14) Similarly, as observed on other members
of Pim family,(15,16) we demonstrated that aberrantly expressed
Pim-3 can inactivate a pro-apoptotic BH3-only Bcl-2-like molecule,
Bad, by phosphorylating its serine residue and eventually prevent
apoptosis in human pancreatic cancer cell lines.(9) These observ-
ations suggest that Pim-3 may contribute to carcinogenesis by
negatively modulating apoptosis.
Our previous northern blotting analysis failed to detect Pim-3
mRNA in normal human endoderm-derived organs including liver,
pancreas and colon.(8) Given that Pim-3 can prevent apoptosis, we
assumed that Pim-3 might be aberrantly expressed in malignant
lesions of the colon and might contribute to colon carcinogenesis.
To address this hypothesis, we examined Pim-3 expression in
human colon cancer tissues and found that Pim-3 protein was
detected in a substantial portion of human colon cancer samples,
particularly at the less advanced stages of cancer development.
Moreover, the ablation of endogenous Pim-3 in the colon cancer
cell line reduced the amount of phosphorylated Bad and eventually
promoted apoptosis. Furthermore, we demonstrated that Pim-3
was co-localized with Bad in cancer cells in human colon
cancer tissues.
Materials and methods
Antibodies. The following antibodies were used: mouse anti-Bad
and rabbit anti-actin antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); rabbit anti-heat shock protein (Hsp)60 antibodies
(StressGen Biotechnologies, Victoria, Canada); Alexa Fluor 488
donkey anti-rabbit IgG, and Alexa Fluor 594 donkey anti-mouse IgG
(Molecular Probes); rabbit anti-phospho-Ser112Bad, anti-phospho-
Ser136Bad, and anti-phospho-Ser155Bad antibodies (Cell Signaling
Technology, Beverly, MA, USA); ImmunoPure peroxidase-
conjugated goat anti-mouse and goat anti-rabbit antibodies (Pierce
Biotechnology, Rockford, IL, USA).
Cell culture. A well-differentiated colon cancer-derived cell line,
SW480(17) was maintained in RPMI-1640 medium (Sigma Chemical);
while a moderately differentiated colon cancer-derived cell
line, HT29,(18) and a poorly differentiated cell line, HCT116(19)
were maintained in McCoy’s 5 A Modified Medium (Invitrogen,
Carlsbad, CA, USA). The media were supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals,
Norcross, GA, USA) and the cells were incubated in a humidified
incubator at 37°C in 5% CO2.
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Colon tissue samples. Colon tissue specimens were obtained
with informed consent from individuals as shown in Table 2. As
controls, colon tissues were also obtained from four patients
with diverticulitis but without any malignant lesions. These
samples were collected and paraffin-embedded at the Toyama
University Hospital with approval from the Human Subjects
Research Ethical Committee of Toyama University, Faculty of
Medicine. An additional human colon tissues was obtained
from a patient upon surgery for colon cancer with his informed
consent and with approval from the Human Subjects Research
Ethical Committee of Kanazawa University Hospital. We separated
the tumor and normal tissue, which was at least 2 cm apart from
the edge of tumor foci and was judged histologically to be free
from adenocarcinoma cells, and stored them immediately at −80°C
until protein extraction.
Preparation of polyclonal anti-Pim-3 antibodies. White Japanese
rabbits were immunized with a synthetic, keyhole limpet hemocyanin-
conjugated Pim-3 peptide (CGPGGVDHLPVKILQPAKAD),
that corresponds to the amino acid residues between 13 and 32
in human Pim-3. This region is well conserved in human and
murine Pim-3, but shows a high diversity with other Pim family
members, Pim-1 and Pim-2.(8) An equal volume of the antigen
(2 mg/mL) and an adjuvant, Titer Max Gold (CytRx, Atlanta,
GA, USA), were mixed and emulsified by sonication. Rabbits
were immunized 11 times (2-week interval), by s.c. injection
of the antigen mixture into their backs. Immunoglobulin (Ig)G
fractions were purified from serum utilizing a Protein G
Sepharose 4 Fast Flow column (Amersham Biosciences AB,
Uppsala, Sweden) according to the manufacturer’s instructions.
The resultant IgG fractions were further purified using HiTrap
NHS-activated HP colum (Amersham Biosciences AB) conjugated
with the peptide used for the immunization. The concentration
of the affinity-purified antibody was determined by measuring
the absorbance at 280 nm.
Immunohistochemical analysis of human colon cancer tissues.
Paraffin-embedded human colon adenocarcinoma tissues were
deparaffinized in xylene, rehydrated through graded concentrations
of ethanol and washed with phosphate-buffered saline (PBS).
Endogenous peroxidase activity was blocked with 3% H2O2(DakoCytomation, Carpinteria, CA, USA) for 5 min. For antigen
retrieval, sections were heated in 10 mM sodium citrate buffer
(pH 6.0), followed by blocking with Non-Specific Staining
Blocking reagent (DakoCytomation). The slides were incubated
with rabbit polyclonal anti-Pim-3 IgG (3 µg/mL) or with normal
rabbit IgG overnight at 4°C. The slides were further incubated
with horseradish peroxidase (HRP)-labeled antirabbit polymer
EnVision + System (DakoCytomation) at room temperature for
30 min. Immune complexes were visualized with Peroxidase
Substrate DAB kit (Vector Laboratories, Burlingame, CA, USA),
counterstained with hematoxylin, dehydrated and coverslipped.
Positive cells exhibit either a supranuclear or cytoplasmic
staining pattern. A researcher without a prior knowledge of the
clinical samples evaluated the proportion of Pim-3-positive
cells in colon carcinoma tissues in a semiquantitative manner,
without assessing the intensities, as follows; (–) absent positive
cells; (+–) positive cells in less than 5% of total; (+) positive
cells with 5–25%; (++) positive cells with 25–50%; and (+++)
positive cells with greater than 50%.
Immunofluorescence analyses. Cells were seeded on Laboratory-
Teck chamber slides (Nalge Nunc International, Naperville, IL,
USA) and incubated at 37°C with 5% CO2. Forty-eight hours later,
they were fixed with 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100/PBS for 10 min. Immunostaining was
performed by incubating the slides with rabbit polyclonal
anti-Pim-3 (3 µg/mL), or with the combination of mouse anti-
Bad (1:30) and rabbit anti-Hsp60 antibodies (1:200), followed
by incubation with Alexa Fluor 488 donkey anti-rabbit and/or
Alexa Fluor 594 donkey anti-mouse (1:100) fluorescent antibodies
for 1 h at room temperature. As a negative control, slides were
incubated with normal donkey serum instead of the primary
antibodies. In some experiments, after washing with PBS,
cells were incubated with propidium iodide (Annexin V-FITC
kit, Bender MedSystems, GmbH, Vienna, Austria; 1 µg/mL) for
1 min. Images were captured on a Carl Zeiss LSM510 confocal
microscope (Carl Zeiss Microimage, Thornwood, NY, USA).
Immunoprecipitation and western blotting. Human colon tissues
were minced into small pieces and homogenized in RIPA Lysis
buffer (Santa Cruz Biotechnology), supplemented with protease
inhibitors. The lysates were sonicated and centrifuged at
20 800 g at 4°C for 15 min. The resultant cell lysates were used
for western blotting with anti-Pim-3 IgG as previously
described.(9) Cell lysates from colon cancer cell lines were
subjected to immunoprecipitation with anti-Pim-3 IgG followed
by western blotting analysis with anti-Pim-3 IgG as previously
described.(9) Cell lysates immunoprecipitated with control
rabbit IgG were used as a negative control, while those from
HEK293 cells transfected with human Pim-3 cDNA were used
as a positive control. In some experiments, mouse anti-Bad
antibody (1:100) was used instead of anti-Pim-3 antibody in
western blot analyses following immunoprecipitation with
anti-Pim-3 antibody.
Transfection with short hairpin RNA (shRNA). SW480, HT29 and
HCT116 cells were transfected with shRNA for Pim-3 (5′-
GCACGUGGUGAAGGAGCGG-3′) and Scramble shRNA (5′-
GCGCGCUUUGUAGGAUUCG-3′), inserted into the pSilencer
3.1-H1 Neo expression vector (Ambion, Austin, TX, USA),
using Lipofectamine 2000 Reagent (Invitrogen) according to the
manufacturer’s instructions. In our preliminary experiments,
Pim-1 and Pim-2 mRNA was faintly detected in SW480, HT29
and HCT116 cells. However, we further confirmed that the
transfection of Pim-3 shRNA reduced the mRNA expression
of Pim-3, but not Pim-1 and Pim-2 (data not shown).
Cell cycle and cell apoptosis analysis. At the indicated time
intervals following the transfection with either Pim-3 or Scramble
shRNA, the cells were harvested and fixed with 70% ethanol at
−20°C. The fixed cells were incubated with 50 µg/mL propidium
iodide (Molecular Probes) and 1 µg/mL RNase A for 30 min at
room temperature. DNA content was then analyzed on a FACS
Calibur system (Becton Dickinson, Bedford, MA, USA). The
distribution of cells in each cell-cycle phase was determined by
using cell ModFitLT Software (Becton Dickinson). In some
experiments, phosphatidylserine exposure level was determined
by staining the cells with human Annexin V-FITC Kit (Bender
MedSystem GmbH, Vienna, Austria), according to the manufac-
turer’s instructions. At least 20 000 stained cells were analyzed
on a FACS Calibur system for each determination.
Determination of Bad proteins after Pim-3 shRNA transfection.
At the indicated time intervals following shRNA transfection, whole
cell lysates were prepared by using CelLytic-M mammalian Cell
Lysis/Extraction Reagent containing complete protein inhibitor
cocktail as previously described.(9) Aliquots (50 µg) of the
obtained supernatants were separated by 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto an Immobilon-P Transfer membrane. After being
saturated with 3% bovine serum albumin (BSA), the membrane
was incubated with rabbit anti-Pim-3, mouse anti-Bad, rabbit
anti-phopho-Ser112Bad, antiphospho-Ser136Bad, or anti-phopho-
Ser155Bad antibodies followed by the incubation with ImmunoPure
peroxidase-conjugated anti-mouse or anti-rabbit IgG. The blotted
membrane was then treated with the Super Signal West Dura
Extended Duration Substrate and signals were detected by LAS-
3000 mini charge-coupled device (CCD) camera.
Statistical analysis. The data on human colon carcinoma tissues
were analyzed statistically by using Spearman’s correlation analysis
to analyze the rank data. P < 0.05 was accepted as statistically
significant.
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In other experiments, data were expressed as mean ± SD and
analyzed by using one-way anova, followed by Fisher’s protected
least significant difference test. Differences were considered
significant, when P < 0.05.
Results
Enhanced Pim-3 protein expression in human colon cancer tissues.
Pim-3-positive cells were not detected in colon tissues that
lacked any malignant lesions (data not shown), or normal colon
epithelium distant to adenocarcinoma (Fig. 1A-a). In contrast,
a substantial number of Pim-3-positive cells were detected in
normal epithelium adjacent to adenocarcinoma tissues (Fig. 1A-b)
or adenoma tissues (Fig. 1A-c), as well as adenocarcinoma
(Figs 1A-d,e). The positive reaction was not observed when control
IgG was used as the primary antibody instead of anti-Pim-3
antibodies (Fig. 1B), indicating the specificity of the reaction.
Pim-3 protein was detected mainly in the cytoplasm of adenoma
and adenocarcinoma cells (Fig. 1A-c–e). Moreover, western
blotting analysis detected Pim-3 protein in tumor but not normal
colon tissue derived from a patient with well-differentiated colon
carcinoma (Fig. 1C), further indicating the specificity of the used
antibody. Although some adenocarcinoma tissues consisted mostly
of Pim-3-positive cells (Fig. 1A-d), positive rates were the highest
in adenoma (Table 1). Poorly differentiated adenocarcinoma (n = 5)
did not show any positive staining (Fig. 1A-f), while well- and
moderately differentiated adenocarcinoma exhibited similar
Pim-3 staining (Figs 1A-c,d, Table 2). Moreover, tumor sizes
and invasive depth did not have any significant effects on the
extent of Pim-3 staining (Table 2). In contrast, the presence of
lymph node or liver metastatic foci resulted in decreased Pim-3
expression, compared with adenocarcinoma without a distant
metastasis (Table 2). When 60 samples from a different group
were simultaneously analyzed for Pim-3 expression in both
primary foci and metastatic lesions, Pim-3 expression in primary
foci did not show any significant correlation with that in
metastatic foci (Table 3). These observations suggest that Pim-3
expression was enhanced more frequently at the early phase
rather than the later stages of colon carcinogenesis when distant
metastasis occurs.
Constitutive Pim-3 expression in human colon cancer cell lines.
Pim-3 expression in colon cancer tissues prompted us to examine
Pim-3 expression in colon cancer-derived cell lines, SW480,
HT29 and HCT116, which are derived from well-, moderately,
and poorly differentiated cancer cells. Reverse transcription
polymerase chain reaction (RT–PCR) analysis detected Pim-3
mRNA in these cell lines (data not shown). Immunoblotting
analysis demonstrated that SW480 and HT29 contained similar
but greater amounts of Pim-3 than HCT116 (Fig. 2a,b). An
immunofluorescence analysis further demonstrated a lower
Pim-3 expression in HCT119, compared with SW480 and HT29
(Fig. 2c), consistent with a lower incidence of Pim-3 expression
in human poorly differentiated colon cancer (Table 2). Because
Pim-3 can inactivate a pro-apoptotic BH3-only protein, Bad by
phosphorylating Ser112,(9) we examined the phosphorylation states
of Bad in these cell lines. Bad was constitutively phosphorylated
at Ser112 and to a lesser degree, Ser136 and Ser155 in these cell lines.
Furthermore, the amounts of total Bad and phospho-Ser112Bad,
but not other phosphorylated forms of Bad, were higher in
SW480 and HT29 than HCT116 cells (Fig. 2a,b).
Enhanced apoptosis of human colon cancer cell lines resulting from
the ablation of endogenous Pim-3 protein. In order to clarify the
role of endogenous Pim-3 in cell survival, we ablated Pim-3 protein
by the transfection into SW480 of Pim-3 shRNA. Transfection
of Pim-3 shRNA, but not Scramble shRNA, into SW480 cells
markedly diminished Pim-3 protein by 48 h post-transfection
(Fig. 3a). The transfection of Pim-3 shRNA resulted in a higher
ratio of sub-G1 cell populations with reduced G1 and G2/M
Fig. 1. Aberrant expression of Pim-3 protein in human colon cancer tissues.
Immunostaining with anti-Pim-3 antibodies was performed on human
normal colon tissue distant to adenocarcinoma (A-a), normal colon
tissue adjacent to adenocarcinoma (A-b), adenoma tissues (A-c and B),
well-differentiated adenocarcinoma (A-d), moderately differentiated
adenocarcinoma (A-e), and poorly differentiated adenocarcinoma (A-f)
were immunostained with either anti-Pim-3 antibodies (A and B-a) or
normal rabbit immunoglobulin (Ig)G (B-b) as described in Materials and
Methods. Representative results are shown here. (Original magnification,
×400.) (C) Western blotting analysis of Pim-3 protein in human colon
cancer tissues. Cell lysates from colon cancer and normal tissues (3 mg)
were subjected to an immunoblotting with anti-Pim-3 antibody as
described in Materials and Methods. HEK293 cells transfected with
human Pim-3 cDNA were used as a positive control.
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populations, compared to the cells transfected with Scramble
shRNA (Fig. 3bi–iii). Moreover, Pim-3 shRNA transfectants
contained a markedly higher ratio of apoptotic cells as
evidenced by enhanced phosphatidylserine externalization
(Fig. 3biv–vi). Similar phenomena were observed when HT29
cells were transfected with Pim-3 shRNA (data not shown).
We next examined the effects of Pim-3 ablation on Bad
phosphorylation. The ablation of Pim-3 reduced the amount
of phospho-Ser112Bad but not the amounts of total Bad and
phospho-Ser136Bad (Fig. 3a). Several lines of evidence indicate
that Bad was translocated from cytoplasm to mitochondria upon
its dephosphorylation.(20) Hence, we explored the intracellular
localization of Bad upon dephosphorylation of Ser112 but Ser136
Bad arising from Pim-3 ablation. We employed anti-Hsp60
antibodies to detect mitochondria, because Hsp60 is exclusively
present in mitochondria.(21) Bad was not co-localized with Hsp60
in untreated cells but Pim-3 ablation induced the co-localization
of Bad with Hsp60 (Fig. 3c), suggesting its mitochondrial
localization. Similar phenomena were observed on another
colon cancer cell line, HT29 (data not shown). Thus, these
observations suggest that Pim-3, aberrantly expressed in human
colon cancer cells, can inactivate the potent pro-apoptotic factor,
Bad, and thereby prevent its translocation to mitochondria, by
phosphorylating Bad Ser112.
Co-localization of Pim-3 with Bad protein in primary human colon
cancer. In order to address whether there was evidence to suggest
that Pim-3 might phosphorylate Bad in primary human colon
cancer cells, we performed a double-color immunofluorescence
analysis on human colon cancer tissues. Pim-3 protein was
detected in tumor cells in 9/10 human colon cancer samples that
we examined. In all these Pim-3-positive samples, Bad protein was
co-localized with Pim-3 proteins in both the horizontal (xy axis)
and orthogonal planes (xz and yz axes) (Fig. 4a). Pim-3 proteins
did not co-localize with glyceraldehyde-3-phosphate dehydrogenase
Table 1. Pim-3 expression in colorectal mucosa, adenoma, and adenocarcinoma
Groups n
Pim-3 expression Positive 
Rate (%)– ± + ++ +++
Non-neoplastic mucosa adjacent to adenocarcinoma 111 85 10 15 1 0 23.4*
Adenoma adjacent to adenocarcinoma 40 5 7 25 3 0 87.5**
Adenocarcinoma 131 60 9 48 10 4 54.2***
Proportion of Pim-3-positive cells were evaluated in mucosa and adenoma, that are adjacent to adenocarcinoma, as well as the adenocarcinoma 
area, as described in Materials and Methods. *, compared with adenoma, P = 0.001, Spearman’s rank correlation coefficient (Rs) = 0.596; **, 
compared with adenocarcinoma, P = 0.008; Rs = 0.202; ***, compared with mucosa, P = 0.001, Rs = 0.347.
Table 2. Pim-3 positive samples were analyzed in correlation with clinicopathological features of colorectal adenocarcinoma
Clinicopathological features n
Pim-3 expression
Positive rate (%) Rs P-value
– +– + ++ +++
Sex 0.057 0.544
Female 46 17 5 18 5 1 63.0
Male 68 31 4 25 5 3 54.4
Age 0.073 0.439
< 60 19 10 1 6 0 2 47.4
= 60 95 38 8 37 10 2 60.0
Tumor size 0.135 0.154
< 4 cm 46 16 2 22 5 1 65.2
= 4 cm 68 32 7 21 5 3 52.9
Invasive depth 0.046 0.626
Above submucosa 16 4 2 9 1 0 75.0
Muscularis propria 13 6 0 7 0 0 53.8
Below subserosa 85 38 7 27 9 4 55.3
Lymph node metastatic foci 0.195 0.038
– 52 17 4 22 7 2 67.3
+ 62 31 5 21 3 2 50.0
Liver metastatic foci 0.459 0.001
– 95 30 8 43 10 4 68.4
+ 19 18 1 0 0 0 5.3
Differentiation 0.121 0.200
Well-differentiated 68 25 7 28 5 3 63.2
Moderately differentiated 41 18 2 15 5 1 56.1
Poorly differentiated 5 5 0 0 0 0 0








– +– + ++ +++
– 34 23 4 7 0 0 32.4 0.188 0.151
+– 4 1 3 0 0 0 75.0
+ 20 10 7 3 0 0 50.0
++ 2 0 1 1 0 0 100
+++ 0 0 0 0 0 0 0.0
Total 60 34 15 11 0 0 43.3
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(GAPDH), a protein that is abundantly present in the cytoplasm
(data not shown). Moreover, an immunoprecipitation with
anti-Pim-3 antibodies co-precipitated Bad in a human colon cancer
tissue (Fig. 4b). These observations would further indicate the
co-localization of Pim-3 with Bad in human colon cancer
cells. Finally, in 6/9 Pim-3-positive samples, Pim-3 protein
co-localized with phospho-Ser112Bad in both the horizontal
(xy axis) and orthogonal planes (xz and yz axes) (Fig. 4c). Thus,
Pim-3 may phosphorylate Bad at Ser112 even in primary colon
cancer, thereby regulating apoptosis of the cancer cells.
Discussion
Orderly apoptosis of colon epithelial cells is essential for normal
colon crypt formation.(10) A partial deregulation of apoptosis
occurs due to the inactivation of both alleles of the APC gene,
the first key event in colon carcinogenesis.(12) Further suppression
of apoptosis occurs as these cells develop additional genetic
mutations and phenotypic changes.(13) However, the molecular
mechanisms underlying apoptosis deregulation in colon
carcinogenesis remain elusive. Accumulating evidence suggests
that the regulation of apoptosis of colon cancer cells involves
several kinases including Erk1/2, p38 mitogen-activated kinase,
and Akt.(22–26) Pim kinases can phosphorylate a similar range
of substrates as Akt and thus can provide survival signals to
various types of tumor cells.(14) Our observation that Pim-3
expression was enhanced in the malignant lesions of endoderm-
derived organs, the liver(8) and pancreas,(9) prompted us to evaluate
Pim-3 expression in colon carcinoma tissue. Indeed, Pim-3 was
expressed in a substantial portion of primary colon cancer tissues.
Moreover, we have determined that aberrantly expressed Pim-3
may counteract apoptosis by phosphorylating a pro-apoptotic
molecule, Bad.
Another member of the Pim family, Pim-1, becomes con-
stitutively active without any alteration in conformation, due to
the absence of any regulatory domains.(27) Pim-3 shows a high
sequence identity with Pim-1, even in the kinase domain and
lacks any regulatory domains.(8) Thus, when aberrantly expressed
in colon cancer cells, Pim-3 can be active without any further
modification. Recently, the human Pim-3 gene has been assigned
to chromosome 22q13. A comparative genomic hybridization
analysis demonstrated that the gain at 22q13.3 represented the
minimal chromosomal changes found specifically in colon
cancer tissues with microsatellite instability.(28) However, we
failed to detect Pim-3 gene amplification in several human colon
cancer cell lines including SW480 and HT29 (unpublished data).
Thus, it is not likely that constitutive enhanced expression of
Pim-3 in colon cancer cells is a result of Pim-3 gene amplification.
Several lines of evidence suggest that a transcription factor,
Stat3, is constitutively activated in colon cancer(29–31) and that both
Pim-1 and Pim-2 can be a transcriptional target of Stat3.(32,33)
Moreover, we also observed that the transfection of a dominant
negative form of Stat3 reduced Pim-3 expression in SW480 cells
(unpublished data), suggesting that Stat3 can regulate Pim-3
gene transcription. Of interest is that Pim-1 can synergistically
induce Stat3-mediated cell cycle progression and anti-apoptotic
process.(32) Aberrantly expressed Pim-3 may also synergistically
augment the Stat3-induced malignant phenotype of colon cancer
as Pim-3 has a remarkable sequence identity with Pim-1. If this
is indeed the case, blocking Pim-3 activity may reduce Stat3
activity and thus inhibit colon cancer progression.
Akt shows a similar substrate specificity as the Pim kinases
including Pim-3 and is presumed to have an essential role in the
regulation of apoptosis.(14) Activation of Akt can contribute to
the pathogenesis of a wide variety of malignancies. Indeed, Roy
et al. demonstrated that activated Akt was detected in a substantial
portion of colon adenoma (57% positive) and adenocarcinoma
(57% positive) but not in normal colonic epithelium and hyper-
plastic polyps.(25) Based on these observations, these authors
claimed that Akt overexpression may be an early event during
colon carcinogenesis. Pim-3 exhibited a similar staining pattern
as Akt. Pim-3 was also detected in normal colon mucosal tissues
that are adjacent to adenocarcinoma but do not exhibit any
morphological abnormalities. Thus, Pim-3 overexpression might
be an earlier event than that of Akt during the development of
the malignant phenotype. Moreover, the incidence of Pim-3
expression was higher in adenoma than adenocarcinoma. We
previously observed that precancerous lesions in liver showed a
higher incidence of Pim-3 expression than hepatocellular carcinoma
lesions.(8) Thus, it is tempting to speculate that aberrant Pim-3
expression might generally have a crucial role in the early phase
but not later phase of carcinogenesis.
Genetic analysis has revealed that somatic missense mutations
in the gene of Bad, a pro-apoptotic BH3-only protein, occur in
a small proportion of colon adenocarcinoma samples.(34) It was
postulated that somatic mutation of Bad may contribute to colon
Fig. 2. Constitutive Pim-3 expression in human colon cancer cell lines,
SW480, HT29 and HCT116. (a) Immunoblotting analysis of Pim-3 and
various forms of Bad proteins in human colon cancer cell lines. Cell
lysates were obtained from human colon cancer cells. Aliquots (2 mg)
were subjected to an immunoprecipitation with anti-Pim-3 antibodies
or control rabbit immunoglobulin (Ig)G, followed by an immunoblotting
with anti-Pim-3 antibodies as described in Materials and Methods.
Other aliquots (50 µg) were immunoblotted with antibodies for various
forms of Bad proteins and β-actin. Representative results from three
independent experiments are shown here. (b) Quantification of Pim-3
and various forms of Bad proteins in colon cancer cells. The band
intensities of Pim-3 and various forms of Bad in Fig. 2A were measured
with NIH Image Analysis Software Ver. 1.62 (NIH, Bethesda, MD, USA)
and were normalized to those of β-actin. Asterisk indicates **, P < 0.01
compared with SW480 cells. (c) Immunofluorescence analysis of Pim-3
protein expression in human colon cancer cell lines. A double-color
immunofluorescence analysis was carried out on human colon cancer
cell lines, HCT116 (left row) and HT29 cells (middle row) and SW480
(right row) with the combination of anti-Pim-3 antibodies and
propidium iodine as described in Materials and Methods. Green and
red indicate Pim-3 protein and nuclei, respectively. Representative
results from three independent experiments are shown here. (Original
magnification, upper panel, ×200; lower panel, ×800. Bars, 20 µm.)
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Fig. 3. Effects of ablation of endogenous Pim-3 protein on Bad phosphorylation and apoptosis. (a) Cell lysates were obtained from human colon
cancer cells, SW480, that were transfected with Pim-3 shRNA, Scramble shRNA, or no shRNA, and the resultant lysates were subjected to
immunoblotting as described in Materials and Methods. Representative results from three independent experiments are shown here. Similar
results are obtained using HT29 cells. (b) A human colon cancer cell line, SW480, was either transfected with Scramble shRNA (i,iv) or Pim-3 shRNA
(ii,iii,v,vi). Cells were harvested 48 h after transfection and subjected to staining with propidium iodide (PI) (i–iii) or combined staining with PI and
annexin V (iv–vi) as described in Materials and Methods. The proportion of cells in each cell cycle phase was determined (i–iii) as described in
Materials and Methods. The number in each quadrant (iv,v) indicates the proportion of the cells present in the quadrant. The intensities of
annexin-V staining are shown in (vi), by overlaying the data in (iv) and vice versa. Representative results from three independent experiments are
shown here. Similar results were obtained using HT29 cells. (c) Immunofluorescence analysis of Bad intracellular localization in human colon cancer
cells. SW480 cells, transfected with Pim-3 shRNA, Scramble shRNA or no shRNA, were seeded onto chamber slides. Thirty-two hours after the
transfection, a double-color immunofluorescence analysis was performed as described in Materials and Methods. Green, red, and yellow represent
Hsp60, Bad, and co-localization of Hsp60 and Bad, respectively. Representative results from three independent experiments are shown here.
(Original magnification, ×1600; bar, 10 µm.)
Fig. 4. Association of Pim-3 with Bad in human colon cancer tissues.
(a) Human colon cancer samples were immunostained with either the
combination of anti-Pim-3 and anti-Bad antibodies as described in
Materials and Methods. The fluorescent images were digitally merged
in the left and right two panels. The box in the left panel indicates the
site, where a picture with a higher magnification was taken.
Representative results from 10 individual samples are shown here.
(Original magnification, left panel, ×200; other panels, ×800. Bars,
50 µm.) (b) Cell lysates were obtained from a human colon cancer
tissue, HeLa cells and HEK293 cells transfected with human Pim-3
cDNA. The cell lysates from a human colon cancer tissues were
subjected to immunoprecipitation with anti-Pim-3 or control rabbit
IgG. HeLa cells express Bad, but not Pim-3, and HEK293 cells express
Pim-3, but not Bad. Hence, Hela cells a were subjected to
immunoprecipitation with anti-Bad. The resultant precipitated were
further subjected to immunoblotting with anti-Bad (upper panel) or
anti-Pim-3 (lower panel) antibodies as described in Materials and
Methods. (c) Human colon cancer samples were immunostained with
either the combination of anti-Pim-3 and antiphosho-Ser112Bad
antibodies as described in Materials and Methods. The fluorescent
images were digitally merged in the left and right two panels. The box
in the left panel indicates the site, where a picture with a higher
magnification was taken. Representative results from 10 individual
samples are shown here. (Original magnification, left panel, ×200;
other panels, ×800. Bars, 50 µm.)
Popivanova et al. Cancer Sci | March 2007 | vol. 98 | no. 3 | 327
© 2007 Japanese Cancer Association
carcinogenesis due to decreased apoptosis-inducing activities of
a mutant Bad, when compared with wild-type Bad. The pro-
apoptotic activity of Bad is regulated by its phosphorylation at
serine residues. Unphosphorylated Bad binds and eventually
inactivates anti-apoptotic family members, primarily Bcl-XL but
also Bcl-2.(35–37) Bad can be inactivated by the phosphorylation
at either Ser112 or Ser136. Phosphorylated Bad loses its capacity
to bind to anti-apoptotic molecules such as Bcl-XL and Bcl-2
and its movement from the surface of mitochondria to the
cytosol requires the 14-3-3 protein. Upon liberation from Bad,
Bcl-XL and Bcl-2 can maintain mitochondrial membrane potential
and subsequently prevent apoptosis.(38,39) In this report, we
demonstrated that Bad is constitutively phosphorylated at Ser112
and to a lesser degree, Ser136 in colon cancer cell lines. Moreover,
the ablation of Pim-3 reduced phosphorylation of Ser112 similarly
observed on human pancreatic cancer cell lines.(9) Furthermore,
our in vitro kinase assay revealed that Pim-3 phosphorylates
Bad Ser112 (unpublished data), which represents an inactive
form of Bad.(15,16) Considering that Bad mutants with lower
pro-apoptotic activities were detected in colon carcinomas,(34)
Pim-3-mediated phosphorylation and subsequent inactivation of
Bad protein may also contribute to colon carcinogenesis by
preventing the apoptosis process.
The Akt consensus phosphorylation site contains arginine at
the −5 and −3 in relation to the phosphorylation site,(40) similar
to that required for Pim-1 activity.(32) Although both Bad Ser136
and Ser112 conform to this motif, Akt preferentially phosphorylates
Bad Ser136.(38) In colon cancer cell lines, Ser112 and to a lesser
extent, Ser136 are constitutively phosphorylated and the abl-
ation of Pim-3 reduced the phosphorylation of Ser112 but not
Ser136. Of interest is that the inhibition of Akt induced apoptosis
of colon cancer cells, without dephosphorylating Bad Ser112 and
Ser136.(41) Our in vitro kinase assay revealed that Pim-3 phospho-
rylates Bad Ser112 (unpublished data) and we observed that the
amount of phosphor-Ser112, but not phosphor-Ser136, Bad was
proportional to the amount of Pim-3 in human colon cancer cell
lines. Moreover, we previously observed that the transfection of
Pim-3 enhanced the phosphorylation of Ser112, but not Ser136,
Bad in human pancreatic cell lines.(9) Thus, it is probable that
Pim-3 directly phosphorylates Bad Ser112 and inactivates Bad,
thereby preventing the apoptosis of colon cancer cells. Thus, the
inhibition of Pim-3 may induce apoptosis of colon cancer cells
in a distinct way from the inhibition of Akt. Moreover, Pim-3
may offer an advantage as a molecular target, due to its selective
expression in malignant lesions of liver,(8) pancreas(9) and colon,
in contrast to the expression of Akt in most normal organs.
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